Halozyme Therapeutics’ (HALO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report released on Wednesday morning,Benzinga reports. They currently have a $68.00 target price on the biopharmaceutical company’s stock.

HALO has been the topic of several other research reports. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded up $0.66 on Wednesday, hitting $47.50. 298,645 shares of the company traded hands, compared to its average volume of 1,358,707. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The business’s 50 day moving average price is $51.12 and its 200-day moving average price is $54.09. The company has a market capitalization of $6.04 billion, a price-to-earnings ratio of 15.73, a P/E/G ratio of 0.43 and a beta of 1.23. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $9,254,244.56. This represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 30,000 shares of company stock worth $1,621,800 in the last three months. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds have recently bought and sold shares of HALO. International Assets Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the second quarter worth about $33,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $49,000. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares in the last quarter. Toth Financial Advisory Corp bought a new stake in Halozyme Therapeutics during the 3rd quarter valued at $57,000. Finally, FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth $65,000. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.